Back

US rules may preserve most pharmaceutical licensing deals with China

Verifying
  • Treasury is drafting rules governing US pharmaceutical investment and licensing activity involving China.
  • Chinese biotech licensing deals totaled $115 billion last year, according to GlobalData.
  • Treasury is unlikely to release pharmaceutical investment rules before Xi Jinping meets Donald Trump next week.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.